TY - JOUR
T1 - Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children
AU - de Sévaux, Joline L.H.
AU - Damoiseaux, Roger A.M.J.
AU - van de Pol, Alma C.
AU - Lutje, Vittoria
AU - Hay, Alastair D.
AU - Little, Paul
AU - Schilder, Anne G.M.
AU - Venekamp, Roderick P.
N1 - Funding Information:
In Bertin 1996, study medications were supplied by a pharmaceutical company (Ethypharm); no further details were provided about the role of this company in the design, conduct, analysis, or reporting of the trial. Two other trials were funded by governmental (non-commercial) grants (Hay 2009; Little 2013). In Hay 2009, study medications were purchased from and provided by two companies (Pfizer and DHP Investigational Medicinal Products); these companies had no role in the design, conduct, analysis, or reporting of the trial. No information about funding sources was provided in Kara 2022.
Funding Information:
Alma C van de Pol (ACvdP) was an investigator of the PIM-POM study, a cluster-randomised clinical trial to optimise pain management in children with acute otitis media, which is funded by a research grant from The Netherlands Organisation for Health Research and Development/SBOH no. 80-83910-98-13006 (van Uum 2020).
Funding Information:
Paul Little (PL) is an Editor of the Cochrane Acute Respiratory Infections Group and an investigator of the OPTIMA study, a pragmatic trial on the effectiveness of analgesic ear drops for children with acute otitis media in primary care, which is funded by a research grant from The Netherlands Organisation for Health Research and Development (grant no. 10060011910003). He was an investigator of the UK primary care-based randomised controlled trial comparing the clinical-and cost-effectiveness of anaesthetic (benzocaine-phenazone) eardrops versus placebo drops and no drops in children aged 12 months to 10 years with acute otitis media (Hay 2019).
Funding Information:
Roger AMJ Damoiseaux (RAMJ) is an Editor of the Cochrane Acute Respiratory Infections Group. Roger is an investigator of the OPTIMA study, a pragmatic trial on the effectiveness of analgesic ear drops for children with acute otitis media in primary care, which is funded by a research grant from The Netherlands Organisation for Health Research and Development (grant no. 10060011910003), and was an investigator of the PIM-POM study, a cluster-randomised clinical trial to optimise pain management in children with acute otitis media, which is funded by a research grant from The Netherlands Organisation for Health Research and Development/SBOH no. 80-83910-98-13006 (van Uum 2020).
Funding Information:
We gratefully thank Alies Sjoukes who contributed to the review first published in 2016 (Sjoukes 2016). The following people conducted the editorial process for this 2023 update. Sign-off Editor (final editorial decision): Mark Jones (Bond University, Australia) and Mieke van Driel (The University of Queensland, Australia). Managing Editor (provided editorial guidance to authors, edited the review, selected peer reviewers, collated peer-reviewer comments): Liz Dooley (Bond University, Australia). Contact Editor (assessed peer-review comments and recommended an editorial decision): Tom Fahey, Department of General Practice, Royal College of Surgeons in Ireland, Dublin, Ireland. Statistical Editor (provided comments): Menelaos Konstantinidis, Li Ka Shing Knowledge Institute, St Michael's Hospital, Unity Health Toronto, Canada. Copy Editor (copy-editing and production): Lisa Winer, Cochrane Central Production Service. Sign-off Editor (final editorial decision): Mark Jones (Bond University, Australia) and Mieke van Driel (The University of Queensland, Australia). Managing Editor (provided editorial guidance to authors, edited the review, selected peer reviewers, collated peer-reviewer comments): Liz Dooley (Bond University, Australia). Contact Editor (assessed peer-review comments and recommended an editorial decision): Tom Fahey, Department of General Practice, Royal College of Surgeons in Ireland, Dublin, Ireland. Statistical Editor (provided comments): Menelaos Konstantinidis, Li Ka Shing Knowledge Institute, St Michael's Hospital, Unity Health Toronto, Canada. Copy Editor (copy-editing and production): Lisa Winer, Cochrane Central Production Service. Peer reviewers (provided comments and recommended an editorial decision): Clinical/content review: Sebastian Straube, BM BCh, MA (Oxon), DPhil, Professor, Division of Preventive Medicine, Department of Medicine, University of Alberta, Canada. Consumer review: Sallie Bernard, parent. Janet Wale, independent consumer advocate. Search review: Justin Clark (Bond University, Australia); Yuan Chi peer reviewed search methods. Clinical/content review: Sebastian Straube, BM BCh, MA (Oxon), DPhil, Professor, Division of Preventive Medicine, Department of Medicine, University of Alberta, Canada. Consumer review: Sallie Bernard, parent. Janet Wale, independent consumer advocate. Search review: Justin Clark (Bond University, Australia); Yuan Chi peer reviewed search methods.
Funding Information:
The study was funded by the National Institute for Health and Care Research Health Technology Assessment programme. The active drugs and matched placebos were purchased from and provided by Pfizer and DHP Investigational Medicinal Products.
Publisher Copyright:
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
PY - 2023/8/18
Y1 - 2023/8/18
N2 - Background: Acute otitis media (AOM) is one of the most common childhood infectious diseases. Pain is the key symptom of AOM and central to children's and parents' experience of the illness. Because antibiotics provide only marginal benefits, analgesic treatment including paracetamol (acetaminophen) and non-steroidal anti-inflammatory drugs (NSAIDs) is regarded as the cornerstone of AOM management. This is an update of a review first published in 2016. Objectives: Our primary objective was to assess the effectiveness of paracetamol (acetaminophen) or NSAIDs, alone or combined, compared with placebo or no treatment in relieving pain in children with AOM. Our secondary objective was to assess the effectiveness of NSAIDs as compared with paracetamol in children with AOM. Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), Issue 5, April 2023; MEDLINE (Ovid, from 1946 to May 2023), Embase (from 1947 to May 2023), CINAHL (from 1981 to May 2023), LILACS (from 1982 to May 2023), and Web of Science Core Collection (from 1955 to May 2023). We searched the WHO ICTRP and ClinicalTrials.gov for completed and ongoing trials (23 May 2023). Selection criteria: We included randomised controlled trials comparing the effectiveness of paracetamol or NSAIDs, alone or combined, for pain relief in non-hospitalised children aged six months to 16 years with AOM. We also included trials of paracetamol or NSAIDs, alone or combined, for children with fever or upper respiratory tract infections if we were able to extract subgroup data on pain relief in children with AOM either directly or after obtaining additional data from study authors. We extracted and summarised data for the following comparisons: paracetamol versus placebo, NSAIDs versus placebo, NSAIDs versus paracetamol, and NSAIDs plus paracetamol versus paracetamol alone. Data collection and analysis: We used standard methodological procedures expected by Cochrane. We rated the overall certainty of evidence for each outcome of interest using the GRADE approach. Main results: We included four trials (411 children) which were assessed at low to high risk of bias. Paracetamol versus placebo. Data from one trial (148 children) informed this comparison. Paracetamol may be more effective than placebo in relieving pain at 48 hours (proportion of children with pain 10% versus 25%, risk ratio (RR) 0.38, 95% confidence interval (CI) 0.17 to 0.85; number needed to treat for an additional beneficial outcome (NNTB) 7; low-certainty evidence). The evidence is very uncertain about the effects of paracetamol on fever at 48 hours (RR 1.03, 95% CI 0.07 to 16.12; very low-certainty evidence) and adverse events (RR 1.03, 95% CI 0.21 to 4.93; very low-certainty evidence). No data were available for our other outcomes of interest. NSAIDs versus placebo. Data from one trial (146 children) informed this comparison. Ibuprofen may be more effective than placebo in relieving pain at 48 hours (proportion of children with pain 7% versus 25%, RR 0.28, 95% CI 0.11 to 0.70; NNTB 6; low-certainty evidence). The evidence is very uncertain about the effect of ibuprofen on fever at 48 hours (RR 1.06, 95% CI 0.07 to 16.57; very low-certainty evidence) and adverse events (RR 1.76, 95% CI 0.44 to 7.10; very low-certainty evidence). No data were available for our other outcomes of interest. NSAIDs versus paracetamol. Data from four trials (411 children) informed this comparison. The evidence is very uncertain about the effect of ibuprofen versus paracetamol in relieving ear pain at 24 hours (RR 0.83, 95% CI 0.59 to 1.18; 2 RCTs, 39 children; very low-certainty evidence); 48 to 72 hours (RR 0.91, 95% CI 0.54 to 1.54; 3 RCTs, 183 children; low-certainty evidence); and four to seven days (RR 0.74, 95% CI 0.17 to 3.23; 2 RCTs, 38 children; very low-certainty evidence). The evidence is very uncertain about the effect of ibuprofen versus paracetamol on mean pain score at 24 hours (0.29 lower, 95% CI 0.79 lower to 0.20 higher; 3 RCTs, 111 children; very low-certainty evidence); 48 to 72 hours (0.25 lower, 95% CI 0.66 lower to 0.16 higher; 3 RCTs, 108 children; very low-certainty evidence); and four to seven days (0.30 higher, 95% CI 1.78 lower to 2.38 higher; 2 RCTs, 31 children; very low-certainty evidence). The evidence is very uncertain about the effect of ibuprofen versus paracetamol in resolving fever at 24 hours (RR 0.69, 95% CI 0.24 to 2.00; 2 RCTs, 39 children; very low-certainty evidence); 48 to 72 hours (RR 1.18, 95% CI 0.31 to 4.44; 3 RCTs, 182 children; low-certainty evidence); and four to seven days (RR 2.75, 95% CI 0.12 to 60.70; 2 RCTs, 39 children; very low-certainty evidence). The evidence is very uncertain about the effect of ibuprofen versus paracetamol on adverse events (RR 1.71, 95% CI 0.43 to 6.90; 3 RCTs, 281 children; very low-certainty evidence); reconsultations (RR 1.13, 95% CI 0.92 to 1.40; 1 RCT, 53 children; very low-certainty evidence); and delayed antibiotic prescriptions (RR 1.32, 95% CI 0.74 to 2.35; 1 RCT, 53 children; very low-certainty evidence). No data were available on time to resolution of pain. NSAIDs plus paracetamol versus paracetamol alone. Data on the effectiveness of ibuprofen plus paracetamol versus paracetamol alone came from two trials that provided crude subgroup data for 71 children with AOM. The small sample provided imprecise effect estimates, therefore we were unable to draw any firm conclusions (very low-certainty evidence). Authors' conclusions: Despite explicit guideline recommendations on the use of analgesics in children with AOM, the current evidence on the effectiveness of paracetamol or NSAIDs, alone or combined, in children with AOM is limited. Paracetamol and ibuprofen as monotherapies may be more effective than placebo in relieving short-term ear pain in children with AOM. The evidence is very uncertain for the effect of ibuprofen versus paracetamol on relieving short-term ear pain in children with AOM, as well as for the effectiveness of ibuprofen plus paracetamol versus paracetamol alone, thereby preventing any firm conclusions. Further research is needed to provide insights into the role of ibuprofen as adjunct to paracetamol, and other analgesics such as anaesthetic eardrops, for children with AOM.
AB - Background: Acute otitis media (AOM) is one of the most common childhood infectious diseases. Pain is the key symptom of AOM and central to children's and parents' experience of the illness. Because antibiotics provide only marginal benefits, analgesic treatment including paracetamol (acetaminophen) and non-steroidal anti-inflammatory drugs (NSAIDs) is regarded as the cornerstone of AOM management. This is an update of a review first published in 2016. Objectives: Our primary objective was to assess the effectiveness of paracetamol (acetaminophen) or NSAIDs, alone or combined, compared with placebo or no treatment in relieving pain in children with AOM. Our secondary objective was to assess the effectiveness of NSAIDs as compared with paracetamol in children with AOM. Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), Issue 5, April 2023; MEDLINE (Ovid, from 1946 to May 2023), Embase (from 1947 to May 2023), CINAHL (from 1981 to May 2023), LILACS (from 1982 to May 2023), and Web of Science Core Collection (from 1955 to May 2023). We searched the WHO ICTRP and ClinicalTrials.gov for completed and ongoing trials (23 May 2023). Selection criteria: We included randomised controlled trials comparing the effectiveness of paracetamol or NSAIDs, alone or combined, for pain relief in non-hospitalised children aged six months to 16 years with AOM. We also included trials of paracetamol or NSAIDs, alone or combined, for children with fever or upper respiratory tract infections if we were able to extract subgroup data on pain relief in children with AOM either directly or after obtaining additional data from study authors. We extracted and summarised data for the following comparisons: paracetamol versus placebo, NSAIDs versus placebo, NSAIDs versus paracetamol, and NSAIDs plus paracetamol versus paracetamol alone. Data collection and analysis: We used standard methodological procedures expected by Cochrane. We rated the overall certainty of evidence for each outcome of interest using the GRADE approach. Main results: We included four trials (411 children) which were assessed at low to high risk of bias. Paracetamol versus placebo. Data from one trial (148 children) informed this comparison. Paracetamol may be more effective than placebo in relieving pain at 48 hours (proportion of children with pain 10% versus 25%, risk ratio (RR) 0.38, 95% confidence interval (CI) 0.17 to 0.85; number needed to treat for an additional beneficial outcome (NNTB) 7; low-certainty evidence). The evidence is very uncertain about the effects of paracetamol on fever at 48 hours (RR 1.03, 95% CI 0.07 to 16.12; very low-certainty evidence) and adverse events (RR 1.03, 95% CI 0.21 to 4.93; very low-certainty evidence). No data were available for our other outcomes of interest. NSAIDs versus placebo. Data from one trial (146 children) informed this comparison. Ibuprofen may be more effective than placebo in relieving pain at 48 hours (proportion of children with pain 7% versus 25%, RR 0.28, 95% CI 0.11 to 0.70; NNTB 6; low-certainty evidence). The evidence is very uncertain about the effect of ibuprofen on fever at 48 hours (RR 1.06, 95% CI 0.07 to 16.57; very low-certainty evidence) and adverse events (RR 1.76, 95% CI 0.44 to 7.10; very low-certainty evidence). No data were available for our other outcomes of interest. NSAIDs versus paracetamol. Data from four trials (411 children) informed this comparison. The evidence is very uncertain about the effect of ibuprofen versus paracetamol in relieving ear pain at 24 hours (RR 0.83, 95% CI 0.59 to 1.18; 2 RCTs, 39 children; very low-certainty evidence); 48 to 72 hours (RR 0.91, 95% CI 0.54 to 1.54; 3 RCTs, 183 children; low-certainty evidence); and four to seven days (RR 0.74, 95% CI 0.17 to 3.23; 2 RCTs, 38 children; very low-certainty evidence). The evidence is very uncertain about the effect of ibuprofen versus paracetamol on mean pain score at 24 hours (0.29 lower, 95% CI 0.79 lower to 0.20 higher; 3 RCTs, 111 children; very low-certainty evidence); 48 to 72 hours (0.25 lower, 95% CI 0.66 lower to 0.16 higher; 3 RCTs, 108 children; very low-certainty evidence); and four to seven days (0.30 higher, 95% CI 1.78 lower to 2.38 higher; 2 RCTs, 31 children; very low-certainty evidence). The evidence is very uncertain about the effect of ibuprofen versus paracetamol in resolving fever at 24 hours (RR 0.69, 95% CI 0.24 to 2.00; 2 RCTs, 39 children; very low-certainty evidence); 48 to 72 hours (RR 1.18, 95% CI 0.31 to 4.44; 3 RCTs, 182 children; low-certainty evidence); and four to seven days (RR 2.75, 95% CI 0.12 to 60.70; 2 RCTs, 39 children; very low-certainty evidence). The evidence is very uncertain about the effect of ibuprofen versus paracetamol on adverse events (RR 1.71, 95% CI 0.43 to 6.90; 3 RCTs, 281 children; very low-certainty evidence); reconsultations (RR 1.13, 95% CI 0.92 to 1.40; 1 RCT, 53 children; very low-certainty evidence); and delayed antibiotic prescriptions (RR 1.32, 95% CI 0.74 to 2.35; 1 RCT, 53 children; very low-certainty evidence). No data were available on time to resolution of pain. NSAIDs plus paracetamol versus paracetamol alone. Data on the effectiveness of ibuprofen plus paracetamol versus paracetamol alone came from two trials that provided crude subgroup data for 71 children with AOM. The small sample provided imprecise effect estimates, therefore we were unable to draw any firm conclusions (very low-certainty evidence). Authors' conclusions: Despite explicit guideline recommendations on the use of analgesics in children with AOM, the current evidence on the effectiveness of paracetamol or NSAIDs, alone or combined, in children with AOM is limited. Paracetamol and ibuprofen as monotherapies may be more effective than placebo in relieving short-term ear pain in children with AOM. The evidence is very uncertain for the effect of ibuprofen versus paracetamol on relieving short-term ear pain in children with AOM, as well as for the effectiveness of ibuprofen plus paracetamol versus paracetamol alone, thereby preventing any firm conclusions. Further research is needed to provide insights into the role of ibuprofen as adjunct to paracetamol, and other analgesics such as anaesthetic eardrops, for children with AOM.
KW - Acetaminophen/therapeutic use
KW - Anti-Bacterial Agents
KW - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
KW - Child
KW - Fever/drug therapy
KW - Humans
KW - Ibuprofen/therapeutic use
KW - Otitis Media/complications
KW - Pain
UR - http://www.scopus.com/inward/record.url?scp=85168273890&partnerID=8YFLogxK
U2 - 10.1002/14651858.CD011534.pub3
DO - 10.1002/14651858.CD011534.pub3
M3 - Review article
C2 - 37594020
SN - 1469-493X
VL - 2023
JO - The Cochrane database of systematic reviews
JF - The Cochrane database of systematic reviews
IS - 8
M1 - CD011534
ER -